Enfusion (NYSE:ENFN) Shares Down 7.3%

Shares of Enfusion, Inc. (NYSE:ENFN) dropped 7.3% during mid-day trading on Thursday . The stock traded as low as $8.87 and last traded at $9.06. Approximately 206,612 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 372,112 shares. The stock had previously closed at $9.77.

Analysts Set New Price Targets

ENFN has been the topic of several recent research reports. Bank of America boosted their price target on Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th. The Goldman Sachs Group cut Enfusion from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $9.00 to $8.00 in a research report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. cut Enfusion from a “neutral” rating to an “underweight” rating and dropped their target price for the stock from $11.00 to $9.00 in a research report on Tuesday, January 30th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.33.

Enfusion Trading Down 5.0 %

The company has a 50 day moving average price of $9.21 and a 200 day moving average price of $9.17. The firm has a market cap of $1.19 billion, a PE ratio of 116.01, a price-to-earnings-growth ratio of 2.79 and a beta of 0.97.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Tuesday, March 12th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $46.49 million for the quarter, compared to analysts’ expectations of $45.56 million. Enfusion had a return on equity of 10.30% and a net margin of 3.45%. As a group, equities research analysts anticipate that Enfusion, Inc. will post 0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Brown Capital Management LLC raised its holdings in Enfusion by 6.5% in the 4th quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock valued at $114,631,000 after acquiring an additional 724,502 shares during the last quarter. Vanguard Group Inc. raised its holdings in Enfusion by 17.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock valued at $31,286,000 after acquiring an additional 512,479 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Enfusion by 17.2% during the 3rd quarter. New York State Common Retirement Fund now owns 1,618,803 shares of the company’s stock worth $14,521,000 after buying an additional 237,841 shares during the last quarter. Wasatch Advisors LP increased its holdings in shares of Enfusion by 34.2% during the 1st quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock worth $7,327,000 after buying an additional 201,771 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Enfusion by 5.7% during the 4th quarter. Wellington Management Group LLP now owns 489,364 shares of the company’s stock worth $4,747,000 after buying an additional 26,464 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.